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Background: The aim of the present study was to evaluate the prevalence and severity of lower limb lymphedema
after pelvic lymphadenectomy and radiotherapy to the pelvic lymph nodes in patients with prostate cancer.
Methods: Twenty-six patients underwent combined treatment for high-risk node-positive prostate cancer at Skåne
University Hospital between April 2008 and March 2011. The treatment consisted of extended pelvic lymphadenec-
tomy followed by androgen deprivation therapy and radiotherapy. The pelvic lymphnodes, prostate and seminal
vesicles were treated with external beam radiotherapy (EBRT) to an absorbed dose of 50 Gy followed by a brachy-
therapy (BT) boost of 2x10 Gy to the prostate only. Twenty-two patients accepted an invitation to a clinical examin-
ation with focus on lower limb swelling. The median time between the end of radiotherapy and examination was
2.2 years (range 1.2–4.1).
Results: Six patients (27%) experienced grade 1 lymphedema and two patients (9%) grade 2 while none had grade
3 or 4 according to the CTC Common Toxicity Criteria scale 4.0. Three patients required treatment with
compression stockings.
Conclusion: Brachytherapy and pelvic EBRT have a low incidence of lymphedema (at median 2.2 y after treatment)
in patients with high-risk node-positive prostate cancer that have undergone pelvic lymph node dissection.
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Lower extremity lymphedema is a complication, which
has not been thoroughly studied in prostate cancer. It typ-
ically occurs after extended node dissection with add-
itional radiation therapy, and it has a large negative effect
on quality of life. There is little information about the rate
of lymphedema after treatment. In a few studies the rate is
mentioned to be 0-10% after extended lymphadenectomy
(ePLND) [1]. In RTOG studies with extended-field irradi-
ation for carcinoma of the prostate about 5% genital and/
or leg edema has been noted and the edema remains
chronic in the majority of the patients [2]. Lymphedema
following treatment for gynecological cancer has been* Correspondence: elisabeth.rasmusson@med.lu.se
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distribution, and reproduction in any mediumstudied in more detail. The prevalence has been reported
to be about 10-20% after pelvic lymph node removal but
with large variations between different cancer sites [3-6].
The onset time seems to be short with the majority
(>80%) of lower limb lymphedema diagnosed within
12 months after surgery [6].
Patients with high-risk prostate cancer represent about
20-35% of the newly diagnosed patients [7]. Mortality is
high if patients are treated with non-curative intent. Ac-
cording to a Swedish nationwide database study pub-
lished in 2011 the mortality at eight years for patients
with locally advanced prostate cancer, Gleason score 8,
treated non-curatively was 52% [8]. The incidence of
node-positive disease is uncertain but has been reported
to be 4-6% [9]. Node-positive disease has traditionally
been considered to be equivalent to systemic disease and
is therefore often treated with sole hormonal therapy;tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patient baseline characteristics
Variable No of patients (n=26) %













Prostate volume (at diagnosis)
<50 16 62
≥50 6 23
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aggressive attitude.
During the last decade many studies have shown sig-
nificant decrease in cancer specific mortality when treat-
ing high-risk patients with combined systemic and local
treatment with curative intention. The local treatment
appears especially important for T3 or node-positive dis-
ease [10-12]. However, patients with Gleason pattern five
have a high risk of clinical failure and death even after
combined treatment with radiation therapy and hormo-
nal therapy [13].
The number of involved lymph nodes and lymph node
density (LND) are of prognostic value with cut-off values
of 2–3 and 20%, respectively [9,12].
External beam radiation therapy (EBRT) combined with
high-dose-rate brachytherapy (HDR-BT) boost, is an ag-
gressive local treatment used for high-risk patients with
good results [14-19]. In some of the studies pelvic lymph
nodes have been included in the EBRT with acceptable
toxicity [20].
The aim of this retrospective study was to evaluate late
toxicity, with focus on lymphedema, in patients with
node-positive prostate cancer treated at our hospital
with ePLND followed by ERBT to prostate/seminal vesi-
cles and pelvic lymph nodes and HDR-BT boost to the
prostate. The study was carried out at the Department
of Oncology at Skåne University Hospital in Malmö and
Lund, Sweden and approved by the Central Research









HT= hormone therapy.Materials and methods
A total of 26 patients with high-risk node-positive pros-
tate cancer underwent combined treatment with HDR-
BT and pelvic irradiation with EBRT following ePLND at
the Department of Oncology at Skåne University Hos-
pital between April 2008 and March 2011. Patient char-
acteristics are shown in Table 1.
No patient had received previous radiation therapy
(RT). All patients were classified as high-risk patients ac-
cording to clinical stage ≥T2c or Gleason score ≥8 or
PSA >20. Patients were all scanned for metastases with
bone scan and/or PET scan and were considered free
from metastatic disease.Lymph node dissection
Twenty-five of the patients had undergone ePLND and
had 1–3 positive lymph nodes. The anatomic extent of
the lymphadenectomy followed general guidelines [21]
and included dissection on but not lateral to the external
arteries up to the ureteric crossing, obturator fossa and
along the internal iliac artery. In two patients only the ob-
turator fossa was dissected. One patient was not dissected
due to pulmonary embolism at the time of diagnosis.Hormonal therapy
All patients received neo-adjuvant hormonal therapy
(HT). Except for one case all patients received a GnRH-
analogue, one was treated with anti-androgen and two pa-
tients were treated periodically with anti-androgen and
GnRH-analogue. Flare prophylaxis with anti-androgen
was provided. Median time between prescription of HT
and start of radiotherapy was 5 months (range 3–
9 months when excluding one outlier where the time
interval was 8 years). Twenty-three patients (88%) re-
ceived adjuvant HT. In most cases HT was planned for
2–3 years.
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The clinical target volume (CTV) of the EBRT included
the prostate, the seminal vesicles and the pelvic lymph
nodes. The planning target volume (PTV) was created
by expanding the CVT iso-tropically with 8–10 mm
margin. CTV was defined according to RTOG recom-
mendation in most cases (18/22). However, large varia-
tions in CTV segmentation were however found in the
reminder of the patients, due to the lack of firm guide-
lines in the start-up of this treatment. EBRT was given
with 3D-CRT (n = 8), IMRT (n = 12) or helical tomother-
apy (n = 2) to a total dose of 50 Gy in 2 Gy daily frac-
tions, 5 days/ week. HDR-BT was given to the prostate
gland with 2 mm margin in two 10 Gy fractions at a two
week interval. The HDR-BT was started at median 13 days
(range 1–22) after the EBRT was completed. Due to logis-
tic reasons four patients received their HDR-BT in the
middle of the EBRT session. All patients completed the
intended course of radiation.
Median time between diagnosis (of prostate cancer)
and start of radiation therapy was 8 months (range 4–
102). Median time between lymph node dissection and
start of radiation therapy was 5 months (range 3–100).
Two patients had lympocele on planning CT. Radiother-
apy details are presented in Table 2.
Lymphedema examination
All 26 patients were invited to participate in an examin-
ation concerning late side effects with focus on lymph-
edema. Twenty-two (85%) patients accepted. Of the four
patients who refused to attend, one had metastatic dis-
ease while the others referred to other reasons.
Written information about the examination was sent
to the participants together with a standard quality of
life questionnaire for follow-up of patients treated for
prostate cancer. Written consent to participate in the
study was received at the visit. At the examination, pa-
tients were interviewed about any symptoms and comor-
bidity and they were physically examined by an oncologist.
Health factors such as body mass index (BMI), smokingTable 2 Radiotherapy structure volumes (n=22)
Structure/Volume Mean volume (cm3) Range (cm3)
PTV T 158 83-272
(prostate/vesiclesa)
PTV N 711 161-1361
(pelvic nodesb)
Treated volumec 1349 520-2107
Irradiated volumed 5832 3630-10810
aVesicles included in PTV T in 7 (32%) patients.
bDefined according to RTOG in 18 (82%) patients.
cThe volume of the body treated to a dose ≥ 47.5 Gy (95% of the
prescribed dose).
dThe volume of the body treated to a dose ≥ 25 Gy (50% of the
prescribed dose).habits and exercise habits were registered. The latter were
registered and classified according to IPAQ-2005 (Inter-
national Physical Activity Questionnaire). Patients were
also asked to assess their concern for relapse and how sat-
isfied they felt with their treatment so far. Their current
PSA was collected from hospital records.
A physiotherapist, specialized in lymphedema, examined
the presence of lower extremity lymphedema following a
protocol including measurements of limb volume and
local tissue water, palpation and questions about symp-
toms related to lymphedema. A geometric volume method
was used to determine limb volume. Total limb volume
was calculated as the sum of geometric segment using the
frustum model [22]. Difference between the limbs was
expressed in percentage (lymphedema relative volume,
LRV). Local tissue water was evaluated with a device that
transmits an ultra-high frequency electromagnetic wave of
300 MHz into an open-ended coaxial probe in contact
with the skin. An electrical parameter, TDC, direct pro-
portional to tissue water content, was calculated [23].
If a patient was found to have lymphedema requiring
treatment he was offered a new appointment. All symp-
toms were classified according to Common Toxicity Cri-
teria scale CTC 4.0 when applicable.Results
Median follow-up time was 2.2 years (range 1. 2–4.1). Half
of the patients had on-going HT at the time of examin-
ation. Their disease was under good biochemical control,
and none of them had any clinical signs of prostate cancer.
Concerning comorbidity, cardiovascular disease was com-
mon. About 60% had a history with hypertension, ische-
mic heart disease, TIA, arrhythmia and /or heart failure.
The majority of the patients were physically very active.
Details are given in Table 3.Lymphedema
Six patients (27%) experienced grade 1 lymphedema
and two patients (9%) grade 2 while none had grade 3
or 4 according to the CTC Common Toxicity Criteria
scale 4.0.
There was no correlation between the reported radio-
therapy volumes presented in Table 2 and lymphedema.
The measurements of LRV between the two lower
extremities showed that that 5/22 patients had a LRV of
more than 5%, two of them had no signs of lymphedema,
one had severe osteoarthritis in one knee and suffered
from chronic intermittent swelling. Two of these five
patients had a LRV of more than 10%; one was born with
a difference in size of the limbs and had only mild leg
swelling.
No edema was registered based upon TDC measure-
ments (0/20).
Table 3 Patient characteristics at time of examination
Variable No. of patients (n=22) %
Follow-up time (years)
- 1-2 9 41
- 2-3 8 36
- 3-4 2 9
- 4-5 3 14
Adjuvant HT
- On-going 11 50
PSA
- <0,1 14 64
- 0,1-1 8 37
Smoking
- On-going 3 14
- Previous 9 41
- Non-smokers 10 45
BMI
- <25 10 45
- 25-30 10 45
- >30 2 9
Level of exercise
- High 7 32
- Moderate 10 45
- Low 5 23
Comorbidity
- Cardio-vascular disease 13 59
- Diabetes mellitus 3 14
- IBD 1 5
- Chronic pain 3 14
- None (of above) 2 9
IBD= inflammatory bowed disease.
HT= hormone therapy.
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symptoms from the legs such as swelling and pain. Two
were treated with compression stockings before the visit
and one patient was diagnosed with lymphedema requir-
ing treatment and was provided with compression
stocknings at the time of examination. Details are pre-
sented in Table 4.
Other side effects
Urinary side effects were common but usually mild, i.e.
CTC grades 1–2. The most common side effects were
signs of obstruction and frequency symptoms, and mild
incontinence was quite common.
Rectal side effects were less common and also usually
mild, i.e. CTC grades 1–2. The most common symptoms
were intermittent rectal haemorrhage, urgency defecationproblems in the morning, proctitis and faecal incontin-
ence. One patient had faecal incontinence CTC grade 3.
Over 70% of the patients had total erectile dysfunction
(ED) and the remaining had milder symptoms.
One patient reported pelvic pain CTC grade 3. This
was a patient with multiple fractures in the pubic bone.
The same patient had also lymphedema CTC grade 2.
Fourteen patients (64%) reported only very mild side
effects, maximum CTC grade 1 except for ED.
Side effects are summarized in Table 5.
Concern from the patients
Ninety per cent of the patients did not worry at all or
only worried a little about recurrence of the disease.
Ninety-five per cent of the patients were very or quite
satisfied with their treatment so far.
Discussion
Results from this single-institution study show accept-
able late toxicity after combined treatment of HDR-BT
and pelvic irradiation with EBRT in patients with high-
risk node-positive prostate cancer previously treated
with extended pelvic lymph node dissection.
Most patients had only mild and manageable late side
effects. A few patients had more marked inconvenience
associated with the treatment such as lymphedema in
combination with pelvic fractures and disabling fecal in-
continence. This level of severe side effects is compar-
able with those found in other studies [17,24]. Most
patients were very active, some even professionally.
Fifty percent of the patients experienced swelling in
the lower extremities, mostly intermittent and the ma-
jority of them were not diagnosed with lymphedema.
The volume difference between the limbs is a major
factor in the CTC grading system. At least two patients
had other medical conditions that explained the volume
difference (osteoarthritis, malformation) but they were still
scored as lymphedema. The true prevalence of treatment-
related lymphedema in this group is thus probably even
lower than presented in the results section, i.e. approxi-
mately 20% grade 1 and 5% grade 2 with three patients
requiring treatment (14%). Even with this disadvantage
we chose to use CTC 4.0 instead of the doctor’s opinion
or radiological methods as this grading system is rec-
ommended for evaluation of the side effects of radio-
therapy [25,26].
The definition of target volumes for radiation most
likely influences the risk for lymphedema. In this study
we did not find a significant relationship between seg-
mented pelvic nodal volumes or treated/irradiated vol-
umes and lymphedema. Note, however, that in three
cases the nodal target volume were delineated far more
caudally than the RTOG recommendations and these
patients were all diagnosed with lymphedema.
Table 4 Lymphedema assessments




<5% 17 77 1 compression
stockings
5-10% 3 14












Tension 5 23 3 legs, 1 knee,
1 knee/leg
Heaviness 4 18 3 legs & thighs, 1 leg
Swelling 11 50 5 legs, 3 thighs, 1 knee,
3 feet, 1 pubic,
1 knee/toe
Pain 6 27 1 sole, 1 limb, 4 thighs
Tingling 1 5 leg
Numbness 2 9 Sole, knee/leg/feet
Cramp 4 18 2 limb, 1 foot, 1 leg
Warmth 1 5 Knee/leg/feet
Life limiting
symptoms




Table 5 Reported side effects according to CTC 4.0 (n=22)
Variable CTC1-2 CTC3-4 Comment
No % No %




-Urinary obstruction 16 73 0 0
-Urinary pain 2 9 0 0
-Urinary frequency 14 64 0 0
-Urinary incontinence 8 36 0 0
-Urinary retention 3 14 0 0
-Hematuria 1 5 0 0
Rectal
-Rectal pain 1 5 0 0
-Proctitis 4 18 0 0
-Fecal incontinence 3 14 1 5
-Diarrhea 2 9 0 0
-Rectal hemorrhage 6 27 0 0
-Urgency defecation
in the morning
6 27 No CTC-grading
Other
-Erectile dysfunction 5 23 16 72 One missing value
-Pelvic Pain 2 9 1 5 Multiple pelvic
fractures
CTC 4.0=Common Toxicity Criteria scale no 4.0.
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proportion of cardio-vascular comorbidity and a rela-
tively high proportion of overweight. However, these
are common conditions in the population as a whole
so the situation for the study population might give a
good estimation of what to expect from this treatment.
It seems important to register this side effect and initi-
ate early intervention since patients could have a long
survival and lymphedema tends to be chronic. Patients
at risk for lymphedema could be diagnosed through
examination after treatment or perhaps, even through
a questionnaire sent to the patients a few months after
treatment.
The high percentage of erectile dysfunction (ED)
found in this study reflects the situation for elderly
men when treated with long-term hormonal therapy in
combination with radiation therapy. We did not have
any baseline ED data in our study. Salomon et al. re-
ported a baseline ED of 21.5% in patients diagnosedwith clinically localized prostate cancer prior to radical
prostatectomy [27].
The patients were generally very content with their
treatment, probably influenced by the fact that their dis-
ease was under control and that they knew they had re-
ceived a treatment with curative intent. The somewhat
long neo-adjuvant HT is explained by the lack of strin-
gent criteria for the systemic and local treatment of this
group of patients.
The median follow-up time was quite short but earlier
studies on lymphedema after lymphadenectomy and
radiotherapy in patients with gynecological cancer have
shown that the majority of lymphedema occurs during
the first year after treatment [6]. A minor increase of the
prevalence might therefore be expected after a longer
follow-up.
Patients with high-risk nodal-positive disease have a
high mortality if left untreated locally [8]. With an accept-
able late toxicity this local treatment definitively seems fa-
vorable for patients in good clinical condition.
In conclusion, this study shows that the frequency of
late complications including lymphedema was low in
patients with high-risk node-positive prostate cancer
treated with extended lymphadenectomy and combined
irradiation with HDR-BT and pelvic EBRT.
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